MDC-735

**MDC-735** is an investigational, allogeneic off-the-shelf macrophage-based oncology therapy being developed by Cellis for solid tumors. Public descriptions characterize it as a macrophage-drug conjugate and bifunctional immunotherapy designed to remodel the tumor microenvironment, directly damage tumor cells, and stimulate antitumor immune memory. Available public materials indicate preclinical to early clinical-transition development, with work spanning platinum-resistant ovarian cancer, glioblastoma, and other solid-tumor models; however, the precise molecular target set and full active-ingredient composition have not been publicly disclosed in sufficient detail to annotate a definitive single target or complete chemical payload structure with high confidence.